Metabolic Health
3 articles

Neuroscience & Mind
How GLP-1 Agonists May Protect the Brain: The Proposed Mechanisms, and What the Evidence Actually Shows
GLP-1 receptor agonists, known for diabetes and obesity treatment, show promise for neuroprotection based on preclinical studies. However, human trial evidence is mixed, and the exact mechanisms, whether direct brain effects or indirect metabolic improvements, are still under investigation.
Dr. Chloe O'Connell·November 8, 2026

Health & Medicine
Obesity disease label challenges clinical definitions and public health
In a landmark January 2025 finding, an international commission concluded that classifying obesity as a single, uniform disease is incompatible with its varied manifestations, according to Nature .
Maria Flores·June 1, 2026

Cosmos & Physics
New Quintuple Agonist Shows Promise for Obesity and Diabetes in Mice
In obese mice, a single experimental drug molecule, a GLP-1R GIPR PPAR quintuple agonist, led to greater weight loss and better blood sugar control than semaglutide (Ozempic) and a standard GLP-1/GIP
Dr. Evelyn Reed·May 18, 2026
